Clearside Biomedical, Inc.
CLSDQ Healthcare Biotechnology
Clearside Biomedical, Inc.’s revenue for fiscal 2024 (year ended December 2024) was $1.7 million, down 79.8% from fiscal 2023. In the quarter to September 2025, revenue fell 80.6%, EPS grew 24.0% and free cash flow grew 8.15%, each against the same quarter a year earlier.
Follow CLSDQ
A Balance Sheet is a financial statement that provides a snapshot of a company's assets, liabilities, and shareholders' equity at a specific point in time. It follows the formula: Assets = Liabilities + Shareholders' Equity. Key components include current and non-current assets, current and long-term liabilities, and equity. The Balance Sheet helps businesses and investors evaluate financial stability, liquidity, and capital structure. It's essential for assessing the company's ability to meet its obligations and fund future operations.
| Older periods | Dec '24 | Mar '25 | Jun '25 | Sep '25 | |
|---|---|---|---|---|---|
Cash and Short Term Investments |
+8 more quarters Free account |
20.02 | 13.63 | 9.38 | 6.80 |
Receivables |
0.51 | 1.54 | 0.82 | 0.27 | |
Other current assets |
0.01 | 0.08 | 0.01 | — | |
Total current assets |
21.27 | 15.96 | 11.79 | 8.25 | |
Property, Plant, Equpment (Net) |
3.23 | 3.15 | 3.07 | 2.98 | |
Long-term assets (Other) |
0.03 | 0.03 | 0.03 | 0.03 | |
Total non-current assets |
3.85 | 3.70 | 3.55 | 3.39 | |
Total Assets |
25.13 | 19.67 | 15.33 | 11.64 | |
Accounts Payable |
1.45 | 1.91 | 1.13 | 0.80 | |
Accrued Expenses |
2.97 | 2.72 | 1.54 | 1.59 | |
Total current liabilities |
4.79 | 5.01 | 3.05 | 2.77 | |
Non-current Liabilities (Other) |
58.86 | 60.33 | 60.87 | 62.76 | |
Total non-current liabilities |
59.19 | 60.57 | 61.02 | 62.82 | |
Total liabilities |
63.98 | 65.58 | 64.07 | 65.59 | |
Additional Paid In Capital |
316.34 | 317.51 | 319.18 | 319.94 | |
Common Stock (Net) |
0.08 | 0.08 | 0.08 | 0.08 | |
Retained Earnings |
(355.27) | (363.50) | (367.99) | (373.96) | |
Common Equity (Total) |
(38.85) | (45.91) | (48.73) | (53.95) | |
Shareholders Equity (Total) |
(38.85) | (45.91) | (48.73) | (53.95) | |
Shareholders Equity and Liabilities (Total) |
25.13 | 19.67 | 15.33 | 11.64 | |
Shares (Common) |
5.11 | 5.15 | 5.24 | 5.23 | |
Shareholders Equity (Tangible) |
(38.85) | (45.91) | (48.73) | (53.95) | |
Net Debt |
(20.02) | (13.63) | (9.38) | (6.80) |